Login to Your Account

Clinic Roundup

Friday, March 18, 2011
Kythera Biopharmaceuticals Inc., of Los Angeles, reported additional efficacy data from a third Phase III study of ATX-101, an adipolytic agent aimed at reducing submental fat (SMF), with results showing a statistically significant difference for the 2 mg/cm2 dose relative to placebo for all Patient-Reported Submental Fat Impact Scale (PR-SMFIS) measures, as well as a composite PR-SMFIS score (p < 0.05.)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription